Literature DB >> 17614938

Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments.

Aaron J Trask1, Carlos M Ferrario.   

Abstract

Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17614938     DOI: 10.1111/j.1527-3466.2007.00012.x

Source DB:  PubMed          Journal:  Cardiovasc Drug Rev        ISSN: 0897-5957


  38 in total

1.  Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat.

Authors:  Vineet C Chitravanshi; Hreday N Sapru
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

Review 2.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Authors:  Michael J Katovich; Justin L Grobe; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.

Authors:  Gerry T M Wagenaar; Rozemarijn M A Sengers; El Houari Laghmani; Xueyu Chen; Melissa P H A Lindeboom; Anton J M Roks; Gert Folkerts; Frans J Walther
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

Review 4.  Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome.

Authors:  Hicham Labazi; Aaron J Trask
Journal:  Pharmacol Res       Date:  2017-07-09       Impact factor: 7.658

Review 5.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

Review 6.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

Review 7.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

Review 8.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 9.  Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure.

Authors:  Irving H Zucker; Harold D Schultz; Kaushik P Patel; Wei Wang; Lie Gao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

Review 10.  New angiotensins.

Authors:  Jasmina Varagic; Aaron J Trask; Jewell A Jessup; Mark C Chappell; Carlos M Ferrario
Journal:  J Mol Med (Berl)       Date:  2008-04-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.